Mersana Therapeutics, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • MRSN (NMS)

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire

PR Newswire • Dec 16

Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout - Yahoo Finance

Yahoo Finance • Dec 15

Day One Biopharmaceuticals to Acquire Mersana Therapeutics - GlobeNewswire

GlobeNewswire • Nov 13

Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout - Investor's Business Daily

Investor's Business Daily • Nov 13

Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC - Fierce Biotech

Fierce Biotech • Nov 13

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Mersana Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Mersana Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Mersana Therapeutics, Inc. have?

Mersana Therapeutics, Inc. has approximately 102 employees.

What industry is Mersana Therapeutics, Inc. in?

Mersana Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Mersana Therapeutics, Inc. a publicly traded company?

Yes, Mersana Therapeutics, Inc. is publicly traded under the ticker symbol MRSN on the NMS. The company has a market capitalization of approximately $0.15 billion.

Where is Mersana Therapeutics, Inc. headquartered?

Mersana Therapeutics, Inc. is headquartered in Cambridge, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.